MRD in AML, Early-Phase Cancer Trials Reality Check, and the Hospital-at-Home Debate
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
MRD in AML, Early-Phase Cancer Trials Reality Check, and the Hospital-at-Home Debate
-
ナレーター：
-
著者：
このコンテンツについて
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt covers three important topics shaping cancer care. A new study confirms that achieving MRD negativity early in AML is critical for long-term survival, reinforcing MRD’s growing role in treatment decisions. We then explore the hard truth about early-phase cancer trials, revealing that only 16.2% of phase 2 treatments ever gain FDA approval—what does this mean for patients enrolling in these studies? Finally, we examine the rapid expansion of Hospital-at-Home care, a model that could change oncology treatment, but also raises concerns about patient safety and healthcare equity. Tune in for the latest updates and insights.